Home  About us  Contact
 

Oral Itraconazole (oral + itraconazole)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

Curvularia,favorable response to oral itraconazole therapy in two patients with locally invasive phaeohyphomycosis

CLINICAL MICROBIOLOGY AND INFECTION, Issue 12 2003
A. SafdarArticle first published online: 12 DEC 200
Curvularia species are ubiquitous and occasionally lead to infections in humans. In immunosuppressed patients, infections are often serious, and systemic dissemination is not uncommon. The optimal antifungal therapy is unclear. I here present two cases, a healthy man with locally invasive, mulicentric paranasal fungal sinusitis, and a case of progressive verrucal distal onychomycosis that developed while the patient was undergoing accelerated chemotherapy for non-Hodgkin's lymphoma. Both patients showed excellent responses to treatment with itraconazole suspension. Oral itraconazole may provide a safe and effective alternative for patients with locally invasive non-disseminated mycoses due to Curvularia species. [source]

Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality

INTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 1 2004
Vahide Baysal MD
Background, Due to the high rate of recurrence, seborrheic dermatitis (SD) represents a therapeutic problem. Aim, To evaluate the role of oral itraconazole in the treatment of SD. Patients and methods, Thirty-two patients with SD were enrolled in the study. All topical and oral treatments were stopped. The patients applied 1% hydrocortisone cream twice daily for 1 month. In addition, they took itraconazole, 200 mg/day, during the first week of the first month and then hydrocortisone cream was stopped and itraconazole (200 mg/day) was given on the first 2 days of the following 11 months. The patients were followed for 2 months without medicine. The severity score was measured at the initial evaluation, and at the first, 12th, and 14th months. Results, Twenty-eight patients completed the study. There was a statistically significant decrease in the mean severity score at the first, 12th, and 14th months. On the final evaluation at the 12th month, 19 of the 28 patients showed a complete improvement, and three patients showed a slight improvement. Conclusions, This study indicates that itraconazole plays an important role in the treatment of SD. [source]

Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Issue 10 2006
AK Gupta
Abstract Background, Oral terbinafine and oral itraconazole are two of the most common agents used for the treatment of toenail dermatophyte onychomycosis. Despite the fact that diabetic patients are more likely to have onychomycosis than normal individuals are, there is little research into the efficacy of standard oral regimens of terbinafine and itraconazole for onychomycosis in the diabetic population. Study design, We present a prospective, randomized, single-blind, parallel group, comparator-controlled, multi-centre study designed to assess the efficacy of the pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks) vs. continuous terbinafine (250 mg once daily for 12 weeks) oral therapies in the treatment of dermatophyte toenail distal and lateral subungual onychomycosis (DLSO) in the diabetic population. Efficacy parameters, Primary efficacy measures included mycological cure rate (negative KOH and culture) and effective cure (mycological cure plus nail plate involvement of 10% or less) at Week 48. Results, At Week 48, mycological cure was attained by 88.2% (30 of 34) and 79.3% (23 of 29) of patients in the itraconazole and terbinafine groups, respectively (P not significant). Effective cure (mycological cure with , 10% of nail plate involvement) was attained by 52.9% (18 of 34) of the itraconazole group and 51.7% (15 of 29) of the terbinafine group (P not significant). Three itraconazole patients experienced side effects in the form of gastrointestinal problems. There were no serious adverse events and no interactions with concomitant medications recorded. Discussion, Both continuous terbinafine and itraconazole pulse therapy are effective and safe in the management of dermatophyte toenail onychomycosis in people with diabetes. [source]

Onychomycosis caused by Alternaria spp. in Tuscany, Italy from 1985 to 1999

MYCOSES, Issue 3-4 2001
C. Romano
Alternaria alternata; Alternaria chlamidospora; Nagelinfektionen; Itraconazol. Summary. Cutaneous phaeohyphomycosis due to Alternaria spp. is reported with increasing frequency, especially in patients with immune deficiency. Onychomycosis caused by this mould is still rarely observed. Here we report nine cases observed in Tuscany in the period 1985,99; the agent was Alternaria alternata in eight cases and Alternaria chlamidospora in one. Diagnosis was made on the basis of repeated direct microscopic mycological examination and culture, confirmed by scanning electron microscope observation of fragments of colonies. In most cases, the clinical manifestations were dystropy and distal subungual hyperkeratosis of one or two nails of the feet or hands. Seven cases were treated with oral itraconazole, successfully in six cases, as clinical and mycological recovery was confirmed at follow-up 1 year later. Zusammenfassung. Kutane Phaeohyphomykosen durch Alternaria spp. werden immer häufiger beschrieben, besonders bei Patienten mit gestörter Infektabwehr. Andererseits sind Onychomykosen durch diese Pilzerreger nur selten zu beobachten. Wir berichten über 9 Fälle von Onychomykosen durch Alternaria spp., die innerhalb eines Zeitraums von 14 Jahren (1985,99) beobachtet worden sind. In 8 Fällen wurde Alternaria alternata und in einem Fall Alternaria chlamidospora isoliert. Die Diagnose wurde nach wiederholtem Nachweis der selben Spezies sowohl in Nativpräparaten als auch in Kultur gestellt und durch elektromikroskopische Untersuchungen der Kolonien bestätigt. Klinisch waren in den meisten Fällen dystrophische Veränderungen und distale subunguale Onychomykose an einem oder mehreren Finger- oder Fußnägeln zu beobachten. 7 Patienten wurden systemisch mit Itraconazol behandelt. In 6 dieser Fälle wurde eine klinische und mykologische Heilung erzielt. Während einjähriger Nachbeobachtungzeit blieben die Patienten rezidivfrei. [source]

Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3

AMERICAN JOURNAL OF HEMATOLOGY, Issue 8 2010
Miho Nara
No abstract is available for this article. [source]

Cutaneous Leishmaniasis: Three Children with Leishmania major Successfully Treated with Itraconazole

PEDIATRIC DERMATOLOGY, Issue 1 2006
J. M. L. White M.R.C.P.
Treatment was successful with oral itraconazole for the children and intralesional sodium stibogluconate for the mother. Cutaneous leishmaniasis should be considered in those with apparently sterile plaques returning from endemic areas. These results suggest that itraconazole, which is ideally suited for use in children, is an effective monotherapy for L. major. [source]

Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients

CLINICAL MICROBIOLOGY AND INFECTION, Issue 2006
D. J. Winston
Abstract Results from randomised, controlled trials and routine clinical experience indicate that itraconazole can be more effective than fluconazole for prevention of invasive fungal infections in allogeneic stem-cell transplant patients. The effective and safe use of prophylactic itraconazole requires an appreciation of the drug's pharmacokinetics, the optimal dosing regimen, and potential drug interactions. Because of the erratic bioavailability of oral itraconazole capsules, only the intravenous (200 mg once-daily) and oral cyclodextrin solution (200 mg twice-daily) formulations of the drug should be used. Prophylaxis should be started after the completion of pre-transplant chemotherapy in order to avoid interactions with chemotherapeutic agents. Patients unable to tolerate oral itraconazole should be given intravenous itraconazole to maintain effective prophylaxis. Post-transplant interactions between itraconazole and immunosuppressive agents or other drugs are generally not problematic, can be easily managed, and need not limit the use of itraconazole. If these guidelines are followed, Aspergillus and other invasive fungal infections can be safely prevented in allogeneic stem-cell transplant patients. [source]